The “Smarter Monopoly” Debate Is Here—and It’s About Orphan Drugs
Big pharma has a reputation for monopolies. But the real fight in drug policy isn’t just about whether exclusivity exists—it’s about what kind of exclusivity we’re willing to pay for, an…
The Smarter Monopoly: Orphan Drug Exclusivity vs. Standard Drug Patents Read Post »
Sell Before the Cliff: A Business Development Playbook for Sterile Manufacturing Suppliers Targeting Biologic Loss of Exclusivity
The market doesn’t wait for your pipeline.
When a biologic approaches loss of exclusivity, the clock starts ticking—not ju…
Evergreen strategies are getting smarter—and so do the teams trying to beat them.
For years, “brand” companies have used a familiar playbook: extend exclusivity not by inventing a cure, but by tightening the legal perimeter around an existing one. New …
GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The life sciences industry has a habit of treating “AI breakthroughs” like weather—interesting, inevitable, and mostly outside our control. But OpenAI’s la…
GPT-Rosalind and Generic Drugs: What OpenAI’s Life Sciences Model Actually Changes Read Post »
Biopharma bizdev teams don’t lose deals because they can’t sell. They lose deals because they’re pitching the wrong time horizon.
In licensing, partnering, and BD strategy, timing is everything—but most teams still treat packaging as an afterthought: a…
OpenAI’s “GPT for life sciences” is being marketed as a shortcut to faster drug discovery. But the real question isn’t whether these models can generate text—it’s what they actually change in the drug development pipeline.
Because in pharma, speed isn’…
GPT-Rosalind: What OpenAI’s Life Sciences Model Actually Does to Drug Development Read Post »
Drug discovery timelines are quietly getting longer—even as the science gets more sophisticated. The bottleneck isn’t just biology. It’s the slow, fragmented workflow between ideation, target validation, experimental design, data interpretation, and do…
Slash drug discovery timelines with GPT-Rosalind Read Post »
Consumers don’t just pay for medicine. They pay for certainty.
That’s the uncomfortable truth behind “branded generics”—a category that often gets dismissed as a marketing relic, when in reality it reflects a deeper economic reality: when patients and …
Why Consumers Pay a “Trust Premium” for Branded Generics Read Post »
Two systems. One fight. How the “patent dance” and Orange Book linkage are shaping the $400B biologics war.
The biologics market is no longer just a science story—it’s a timing story.
At stake is a staggering number: $400 billion in biologics revenue, …
The real fight doesn’t start when the patent is granted—it starts when it’s about to expire.
For years, the pharmaceutical playbook has been framed as a straight line: patent protection buys time, generic entry follows, and everyone moves on. But the m…